Literature DB >> 8563735

Cytomegalovirus infection induces expression of 60 KD/Ro antigen on human keratinocytes.

J Zhu1.   

Abstract

To investigate the effect of human cytomegalovirus (CMV) infection on the expression of Ro autoantigen in human keratinocytes, the binding of anti-Ro peptide antibodies (anti-60 KD/Ro, anti-52 KD/Ro and anti-calreticulin) to cultured human keratinocytes was detected by fixed cell enzyme-linked immunoassay (ELISA), immunofluorescence, flow cytometry (FACS) analysis and immunoblotting. There was a significant increase in the binding of anti-60 KD/Ro antibody but not anti-52 KD/Ro or anti-calreticulin antibody to the surface of cultured keratinocytes at 24 h after CMV infection compared with uninfected cells, by ELISA and immunofluorescence. Surface binding of anti-60 KD/Ro was found in 71.2% (+/- 5.5%) of CMV-infected cells compared with 26.2% (+/- 4.1%) of untreated cells (P < 0.05) by FACS analysis. Similar observations were made with a human serum which contained anti-60 KD/Ro antibodies. Immunoblotting was used to analyse total cellular 60 KD/Ro antigen expression in keratinocytes infected with CMV or without infection. No increase in the intensity of the 60 KD band was found in extracts of the CMV-infected cells, suggesting that the 60 KD/Ro antigen is redistributed from the cytoplasm to the cell surface after viral infection. The effects of CMV infection on cell cultures were compared with those of ultraviolet B (UVB) irradiation. The 60 KD/Ro, 52 KD/Ro and calreticulin were all induced on the UVB-irradiated cell surface but not significant synergistic effect of UVB and CMV was found. This study provides evidence that CMV infection induced 60 KD/Ro antigen expression on the surface of human keratinocytes, suggesting that CMV may play a role in development of skin lesions in systemic lupus erythematosus (SLE).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563735     DOI: 10.1177/096120339500400511

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Correlation between systemic lupus erythematosus and cytomegalovirus infection detected by different methods.

Authors:  Jing Chen; Huidi Zhang; Peirong Chen; Qiaoai Lin; Xiaochun Zhu; Lifang Zhang; Xiangyang Xue
Journal:  Clin Rheumatol       Date:  2015-03-10       Impact factor: 2.980

3.  Kaposi's sarcoma-associated herpesvirus can productively infect primary human keratinocytes and alter their growth properties.

Authors:  F Cerimele; F Curreli; S Ely; A E Friedman-Kien; E Cesarman; O Flore
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity.

Authors:  Ben Yu-Jih Su; Cheng-Yu Su; Shan-Fu Yu; Chung-Jen Chen
Journal:  Med Microbiol Immunol       Date:  2007-02-23       Impact factor: 3.402

5.  Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice.

Authors:  Ao-Ho Hsieh; Yí-Jyun Jhou; Chung-Ting Liang; Mingi Chang; Shih-Lien Wang
Journal:  Arthritis Res Ther       Date:  2011-10-11       Impact factor: 5.156

6.  B cell epitope of human cytomegalovirus phosphoprotein 65 (HCMV pp65) induced anti-dsDNA antibody in BALB/c mice.

Authors:  Ao HoHsieh; Chin Man Wang; Yeong-Jian Jan Wu; Albert Chen; Ming-I Chang; Ji-Yih Chen
Journal:  Arthritis Res Ther       Date:  2017-03-21       Impact factor: 5.156

7.  Human cytomegalovirus pp65 peptide-induced autoantibodies cross-reacts with TAF9 protein and induces lupus-like autoimmunity in BALB/c mice.

Authors:  Ao-Ho Hsieh; Chang-Fu Kuo; I-Jun Chou; Wen-Yi Tseng; Yen-Fu Chen; Kuang-Hui Yu; Shue-Fen Luo
Journal:  Sci Rep       Date:  2020-06-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.